New combo therapy shows promise for Tough-to-Treat gout

NCT ID NCT04762498

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a gout medication called pegloticase (KRYSTEXXA) given every 4 weeks along with weekly methotrexate pills in 54 adults with severe gout that didn't respond to standard treatments. The goal was to see if this combination could lower uric acid levels and keep them low. The results help determine the best dose for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GOUT UNCONTROLLED GOUT

Contacts and locations

Locations

Altoona Center for Clinical Research

Duncansville, Pennsylvania, 16635, United States
Arizona Arthritis & Rheumatology Research, PLLC

Glendale, Arizona, 85306, United States
Arthritis Clinic: Western Washington Medical Group

Bothell, Washington, 98021, United States
Arthritis Northwest PLLC

Spokane, Washington, 99204, United States
Biopharma Informatic, LLC

Houston, Texas, 77043, United States
East Bay Rheumatology Medical Group, Inc.

San Leandro, California, 94578, United States
GCP Clinical Research

Tampa, Florida, 33064, United States
Napa Research Center

Pompano Beach, Florida, 33064, United States
Orthopedic Physicians Alaska

Anchorage, Alaska, 99508, United States
ProHealth Research Center

Doral, Florida, 33166, United States
Shelby Clinical Research, LLC

Shelby, North Carolina, 28150, United States
The Center for Rheumatology and Bone Research

Wheaton, Maryland, 20902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.